Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

A WOMAN has left people with their jaws on the floor after sharing her epic Mounjaro weight loss journey. Mum Lisa jumped on ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Novo Nordisk launches Ozempic in India, a type 2 diabetes treatment with weight-loss benefits, starting at ₹2,200 per week.

A major moment in India’s fight against type-2 diabetes arrived this week with the launch of Ozempic, the globally popular semaglutide drug known for its strong effects on blood sugar control and ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Novo Nordisk launches Ozempic in India, targeting the fast-growing diabetes and obesity market ahead of generic competition.

Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...

Novo Nordisk has today launched Ozempic in India, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.